Rieske相关文献与解析，生知库 | 链接生命科学的每一步

Variability in mountain pine beetle (Coleoptera: Curculionidae) gene expression in response to increasing concentrations of species-specific double-stranded RNA

山松象甲（鞘翅目：象甲科）基因表达对物种特异性双链RNA浓度增加的响应存在变异性

期刊:Journal of Insect Science

影响因子:2

doi:10.1093/jisesa/ieag004

Bickler, Kylie J; Bragg, Zachary; Pampolini, Flávia; Kyre, Bethany R; Rieske, Lynne K

发表日期：2026

文献求助收藏

Root uptake, translocation and persistence of EAB-specific dsRNA in ash seedlings

白蜡树幼苗对EAB特异性dsRNA的根系吸收、转运和持久性

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-025-90266-y

Pampolini, Flavia; Rieske, Lynne K

发表日期：2025

文献求助收藏

First molecules to reactivate RASG12V GTPase activity

首个重新激活 RASG12V GTPase 活性的分子

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-13580-8

Aneta Wlodarczyk, Cezary Treda, Marcin Pacholczyk, Adrianna Rutkowska, Marta Wegierska, Amelia Kierasinska-Kalka, Katarzyna Wasiak, Damian Ciunowicz, Dagmara Grot, Pawel Glowacki, Ewelina Stoczynska-Fidelus #, Piotr Rieske #

RAS

发表日期：2025

文献求助收藏

The complex journey of targeting RAS in oncology

肿瘤学中靶向 RAS 的复杂历程

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-14033-y

Wasiak, Katarzyna; Ciunowicz, Damian; Kierasińska-Kałka, Amelia; Węgierska, Marta; Pacholczyk, Marcin; Rieske, Piotr; Stoczyńska-Fidelus, Ewelina

Regulation of CAR transgene expression to design semiautonomous CAR-T

调控CAR转基因表达以设计半自主CAR-T细胞

期刊:Molecular Therapy Oncology

影响因子:5.3

doi:10.1016/j.omton.2024.200833

Głowacki, Paweł; Tręda, Cezary; Rieske, Piotr

The hope, hype and obstacles surrounding cell therapy

细胞疗法的希望、炒作和障碍

期刊:Journal of Cellular and Molecular Medicine

影响因子:4.2

doi:10.1111/jcmm.18359

Tręda, Cezary; Włodarczyk, Aneta; Rieske, Piotr

细胞生物学

发表日期：2024

文献求助收藏

Optimization model for multi-products multi-periods multi-suppliers raw-material selection and composition, and order quantity problem with one-year minimum order quantity contract

针对多产品、多周期、多供应商的原材料选择与配比以及订货量问题（含一年期最低订货量合同），提出了一种优化模型。

期刊:MethodsX

影响因子:1.9

doi:10.1016/j.mex.2023.102350

Fadhli, Mohammad Rizka; Uttunggadewa, Saladin; Hadianti, Rieske; Pudjaprasetya, Sri Redjeki

发表日期：2023

文献求助收藏

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy

酪氨酸激酶抑制剂治疗胶质母细胞瘤细胞后 EGFRvIII 表位可及性增强，为免疫治疗创造更多机会

期刊:International Journal of Molecular Sciences

影响因子:0.7

doi:10.3390/ijms24054350

Cezary Tręda, Aneta Włodarczyk, Marcin Pacholczyk, Adrianna Rutkowska, Ewelina Stoczyńska-Fidelus, Amelia Kierasińska, Piotr Rieske

Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy

FQAD 患者的再生困难可能会限制基于 iPSc 的细胞疗法的使用

期刊:Stem Cell Research

影响因子:7.1

doi:10.1186/s13287-022-02886-0

Dagmara Grot, Katarzyna Wasiak, Jerzy Tyszkowski, Ewelina Stoczynska-Fidelus, Tomasz P Ochedalski, Piotr Rieske

The New Wave of Gene and Cell Therapies Across Diseases

基因和细胞疗法在多种疾病领域的新浪潮

Variability in mountain pine beetle (Coleoptera: Curculionidae) gene expression in response to increasing concentrations of species-specific double-stranded RNA

山松象甲（鞘翅目：象甲科）基因表达对物种特异性双链RNA浓度增加的响应存在变异性

Root uptake, translocation and persistence of EAB-specific dsRNA in ash seedlings

白蜡树幼苗对EAB特异性dsRNA的根系吸收、转运和持久性

First molecules to reactivate RASG12V GTPase activity

首个重新激活 RASG12V GTPase 活性的分子

The complex journey of targeting RAS in oncology

肿瘤学中靶向 RAS 的复杂历程

Regulation of CAR transgene expression to design semiautonomous CAR-T

调控CAR转基因表达以设计半自主CAR-T细胞

The hope, hype and obstacles surrounding cell therapy

细胞疗法的希望、炒作和障碍

Optimization model for multi-products multi-periods multi-suppliers raw-material selection and composition, and order quantity problem with one-year minimum order quantity contract

针对多产品、多周期、多供应商的原材料选择与配比以及订货量问题（含一年期最低订货量合同），提出了一种优化模型。

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy

酪氨酸激酶抑制剂治疗胶质母细胞瘤细胞后 EGFRvIII 表位可及性增强，为免疫治疗创造更多机会

Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy

FQAD 患者的再生困难可能会限制基于 iPSc 的细胞疗法的使用